Ditching Big Drugmakers for Biotech Brings Leukemia Boon: Health
This article is for subscribers only.
Fifty-five, pensionless and assuming he’d have to work until he died, Roger Ulrich had a decision to make. After two decades in the pharmaceutical industry, his position at Merck & Co. had been phased out.
Instead of joining another big drug company, where he could expect a steady income and relative job security, Ulrich took a leap. He teamed with two partners, raised seed funding and founded a biotechnology company, making a bet on an industry characterized by risk.